Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

I2032

Sigma-Aldrich

Monoclonal Anti-Insulin-Like Growth Factor Binding Protein-1 antibody produced in mouse

clone 33627.11, purified immunoglobulin, lyophilized powder

Sinonimo/i:

Anti-IGFBP-1

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Numero MDL:
Codice UNSPSC:
51111800
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

Coniugato

unconjugated

Forma dell’anticorpo

purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

33627.11, monoclonal

Stato

lyophilized powder

Reattività contro le specie

human

tecniche

capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL

Isotipo

IgG1

N° accesso UniProt

Temperatura di conservazione

−20°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... IGFBP1(3484)

Descrizione generale

The effects of insulin-like growth factors (IGF) are modulated by a family of insulin-like growth factor binding proteins 1-6. (IGFBPs -1-6). IGFBP-1 is secreted as an endocrine factor by liver, kidneys, decidua and in human amniotic fluid, but has the ability to signal in autocrine and paracrine fashion. Post-translational modifications such as ubiquitination, glycosylation and phosphorylation alter the activity of IGFBPs. Phosphorylation of IGFBP-1 is mainly mediated by Casein kinase I and II and cAMP-dependent protein kinases. IGFBP-1 alters the bioavailability of IGF in the serum by binding and sequestration so that a regulated amount id available to act on the target cells. The functions of IGFBP-1 are most important in the physiology of female reproductive system in mammals, for growth and development of the developing fetus
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.

Specificità

The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.

Immunogeno

purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.

Applicazioni

Anti- Insulin-Like Growth Factor Binding Protein-1 antibody may be used for immunoblotting at a working concentration of 1-2 μg/ml. For ELISA, a working concentration of 2 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 10-40 μg/ml).

Stato fisico

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline.

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

D J Fowler et al.
Human reproduction update, 6(5), 495-504 (2000-10-25)
Insulin-like growth factor-1 (IGFBP-1) is particularly important in human female reproductive physiology, where it is involved with other factors in a complex system which regulates menstrual cycles, puberty, ovulation, decidualization, implantation and fetal growth. This has implications for clinical obstetrics
Terry J Smith
Pharmacological reviews, 62(2), 199-236 (2010-04-16)
This topically limited review explores the relationship between the immune system and insulin-like growth factors (IGF-I and IGF-II) and the proteins through which they act, including IGF-I receptor (IGF-IR) and the IGF-I binding proteins. The IGF/IGF-IR pathway plays important and
M Westwood
Reviews of reproduction, 4(3), 160-167 (1999-10-16)
Insulin-like growth factors and their binding proteins are key regulators of fetal and maternal tissue growth and development during human pregnancy. Insulin-like growth factors, particularly IGF-II, are produced in abundance by the trophoblast cells of the placenta, whereas one of
K M Kelley et al.
The international journal of biochemistry & cell biology, 28(6), 619-637 (1996-06-01)
The IGFBPs are a family of homologous proteins that have co-evolved with the IGFs and that confer upon the IGF regulatory system both functional and tissue specificity. IGFBPs are not merely carrier proteins for IGFs, but hold a central position
Ali Vaziri-Gohar et al.
Molecular and cellular endocrinology, 422, 160-171 (2015-12-23)
Tamoxifen, a selective estrogen receptor modulator, is a commonly prescribed adjuvant therapy for estrogen receptor-α (ERα)-positive breast cancer patients. To determine if extracellular factors contribute to the modulation of IGF-1 signaling after tamoxifen treatment, MCF-7 cells were treated with IGF-1 in

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.